Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Lung Cancer Markers

Lung cancer primarily encompasses non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), each with unique characteristics and implications for patient management. Techniques including Western blots, ELISA, flow cytometry, co-immunoprecipitation, and immunohistochemistry can distinguish among the different types of lung cancer and provide vital information about cell proliferation and disease progression, which is critical for the early detection, prognosis/monitoring, and treatment of the disease.

NeoBiotechnologies proudly offers a comprehensive selection of antibodies for lung cancer research (see the table below), with a particular emphasis on IHC-validated antibodies targeting lung cancer protein markers. Our antibodies are rigorously validated for specificity, ensuring precise and reliable results. 

Notable lung cancer markers:

  • Epidermal Growth Factor Receptor (EGFR): EGFR mutations or overexpression are common in non-small cell lung cancer (NSCLC). Targeted therapies, such as tyrosine kinase inhibitors (TKIs), are used for patients with EGFR mutations.
  • ALK (Anaplastic Lymphoma Kinase): ALK rearrangements are found in a subset of NSCLC cases. Targeted therapies like crizotinib are used to treat ALK-positive lung cancer.
  • ROS1 (c-ros oncogene 1): ROS1 rearrangements are another targetable alteration in NSCLC. Crizotinib and other ALK/ROS1 inhibitors are used in treatment.
  • PD-L1 (Programmed Death-Ligand 1): PD-L1 expression on tumor cells can indicate potential responsiveness to immune checkpoint inhibitors, such as pembrolizumab and nivolumab, for advanced NSCLC.
  • KRAS (Kirsten Rat Sarcoma viral oncogene homolog): KRAS mutations are common in lung cancer, especially in adenocarcinoma. They can influence prognosis and treatment decisions.
  • p53 (Tumor Protein 53): TP53 mutations are found in many lung cancers and may be associated with a worse prognosis.
  • RET (Rearranged During Transfection): RET fusions are a targetable alteration in NSCLC, and specific inhibitors like selpercatinib and pralsetinib are used in treatment.
  • BRAF (v-Raf murine sarcoma viral oncogene homolog B1): BRAF V600E mutations are found in some NSCLC cases and can be targeted with therapies like dabrafenib and trametinib.
  • NTRK (Neurotrophic Tyrosine Kinase Receptor): NTRK fusions are rare but actionable alterations in NSCLC, and larotrectinib and entrectinib are used for treatment.
  • Squamous Cell Carcinoma Antigen (SCCA): a marker used for squamous cell carcinoma, a subtype of NSCLC.
  • TTF-1 (Thyroid Transcription Factor-1): an immunohistochemical marker that can help identify lung adenocarcinomas and other tumors of lung origin.
  • CEA (Carcinoembryonic Antigen): levels can be elevated in lung cancer, and this marker is often used for monitoring treatment response and disease recurrence.
  • MUC1 (Mucin 1): a protein overexpressed in many lung cancers, particularly adenocarcinomas.
  • ProGRP (Pro-Gastrin-Releasing Peptide): a marker for small cell lung cancer (SCLC) and can be used for diagnosis and monitoring.
  • NSE (Neuron-Specific Enolase): a general marker used in SCLC cases and can be indicative of the tumor burden.
  • Chromogranin A: a marker for neuroendocrine tumors, including SCLC.

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.